Dyne Therapeutics (NASDAQ:DYN) Hits New 1-Year High – Here’s What Happened

Posted by Stanley Muller on Jul 27th, 2026

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $25.11 and last traded at $25.11, with a volume of 5030 shares traded. The stock had previously closed at $24.44.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on DYN. Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, July 6th. Cantor Fitzgerald began coverage on shares of Dyne Therapeutics in a report on Thursday. They set an “overweight” rating for the company. Sanford C. Bernstein upped their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a report on Friday, May 15th. Finally, TD Cowen assumed coverage on shares of Dyne Therapeutics in a research report on Friday, June 26th. They set a “buy” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.17.

View Our Latest Stock Report on Dyne Therapeutics

Dyne Therapeutics Stock Up 2.7%

The firm has a market capitalization of $4.69 billion, a P/E ratio of -7.80 and a beta of 1.06. The firm’s 50-day moving average is $20.38 and its 200 day moving average is $18.62. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same period in the prior year, the firm posted ($1.05) EPS. As a group, equities research analysts predict that Dyne Therapeutics, Inc. will post -3.01 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 297,211 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $23.26, for a total transaction of $6,913,127.86. Following the completion of the transaction, the director owned 2,962 shares of the company’s stock, valued at $68,896.12. This represents a 99.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Brian S. Posner purchased 2,000 shares of the firm’s stock in a transaction dated Monday, June 8th. The shares were acquired at an average cost of $16.94 per share, with a total value of $33,880.00. Following the completion of the purchase, the director directly owned 24,500 shares in the company, valued at approximately $415,030. This represents a 8.89% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders have bought 9,000 shares of company stock valued at $156,800 and have sold 1,892,879 shares valued at $40,500,030. 9.46% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in DYN. Handelsbanken Fonder AB bought a new position in Dyne Therapeutics in the second quarter valued at $1,182,000. Perceptive Advisors LLC boosted its stake in shares of Dyne Therapeutics by 34.2% during the 1st quarter. Perceptive Advisors LLC now owns 4,668,839 shares of the company’s stock worth $84,646,000 after buying an additional 1,189,895 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Dyne Therapeutics by 63.5% during the 1st quarter. Bank of America Corp DE now owns 1,443,313 shares of the company’s stock worth $26,167,000 after buying an additional 560,391 shares during the last quarter. California State Teachers Retirement System grew its holdings in shares of Dyne Therapeutics by 15.6% in the 1st quarter. California State Teachers Retirement System now owns 139,663 shares of the company’s stock valued at $2,532,000 after acquiring an additional 18,863 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in shares of Dyne Therapeutics by 267.6% in the 1st quarter. Royal Bank of Canada now owns 68,188 shares of the company’s stock valued at $1,236,000 after acquiring an additional 49,641 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.